TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Cardiol Therapeutics ( (TSE:CRDL) ).
On November 13, 2025, Cardiol Therapeutics announced it received a U.S. patent allowance for its heart drugs, CardiolRx™ and CRD-38, extending intellectual property protection until late 2040. This milestone strengthens Cardiol’s market position by expanding its intellectual property portfolio in the U.S., the world’s largest pharmaceutical market, and supports its ongoing clinical programs for heart disease treatments, including the Phase III MAVERIC trial in recurrent pericarditis and the ARCHER trial in acute myocarditis.
The most recent analyst rating on (TSE:CRDL) stock is a Buy with a C$8.00 price target. To see the full list of analyst forecasts on Cardiol Therapeutics stock, see the TSE:CRDL Stock Forecast page.
Spark’s Take on TSE:CRDL Stock
According to Spark, TipRanks’ AI Analyst, TSE:CRDL is a Underperform.
Cardiol Therapeutics faces substantial financial challenges, primarily driven by ongoing losses and negative cash flow. The stock’s technical indicators suggest mixed momentum, and its valuation is constrained by a negative P/E ratio. However, promising clinical developments and strategic advancements in heart disease treatments provide some positive outlook, though these are not sufficient to offset the financial and technical concerns.
To see Spark’s full report on TSE:CRDL stock, click here.
More about Cardiol Therapeutics
Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease. The company’s lead product, CardiolRx™, is targeted at treating conditions such as pericarditis, myocarditis, and heart failure. Cardiol is also developing CRD-38, a novel subcutaneous drug for inflammatory heart disease.
Average Trading Volume: 153,636
Technical Sentiment Signal: Sell
Current Market Cap: C$144.4M
For detailed information about CRDL stock, go to TipRanks’ Stock Analysis page.